TORONTO and WINNIPEG, Aug. 16 /CNW/ - Cangene Corporation today reports that its contract with the U.S. Centers for Disease Control and Prevention for the supply of Vaccinia Immune Globulin Intravenous (Human) (“VIG”) has been extended for five more years. The original five-year contract was signed in August 2002, and under that contract Cangene developed and delivered VIG product to the U.S. Strategic National Stockpile (“SNS”). Although a supply of product is already maintained within the SNS, the extended contract supports licensing requirements, ongoing stability studies, further clinical testing and development projects, and could provide for future orders.
